๐ฃ๐๐๐ฐ๐ต๐ฒ๐ฑ๐ฒ๐น๐ถ๐ฐ ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐ ๐๐๐น๐ & ๐๐๐ด๐๐๐
While many of us had the chance to enjoy a vacation this summer, psychedelic researchers were hard at work
We've rounded up key papers from the past 2 months ๐
https://blossomanalysis.com/psychedelic-research-recap-july-august-2022/ ๐งต 1/6
Results from the first trial using psilocybin to treat alcoholism are promising
"Psilocybin administered in combination with psychotherapy produced robust decreases in the percentage of heavy drinking days"
https://twitter.com/blossomact/status/1562701823643127808 2/6
The jury's still out on microdosing
A study using @QuantCitizen was in favour of microdosing but lacked placebo control & blinding
@ETagliazucchi et al found no improvements in well-being, creativity & cognitive function in a double-blind RCT 3/6
New tools for researchers
@drrosalindwatts et al developed & validated the Watts Connectedness Scale to measure feelings of connectedness
Based on the REBUS model, Richard Zeifman et al have begun developing RElaxed Beliefs Questionnaire (REB-Q) 4/6
Could at-home ketamine therapy soon become a reality?
Using real-world evidence, researchers found that sublingual ketamine tablets taken at home reduced measures of depression & anxiety
We looked at what they did here:
https://twitter.com/blossomact/status/1547924309888233473 5/6
In case you were enjoying your vacation this summer and missed the latest developments in psychedelic research - you can check out the full recap ๐
https://blossomanalysis.com/psychedelic-research-recap-july-august-2022/ 6/6
0
LinkedIn Post